PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2021-12-02 (108)

Date Title Company
02-Dec-2021 Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations Businesswire